gutflix
GI learning, personalised

Summary

PURASTAT MULTICENTRIC REGISTRY: RESULTS FROM THE ITALIAN EXPERIENCE

Vittoria Stigliano

UEG Week Copenhagen 2023 Poster

October 15, 2023

A prospective Italian multicentre registry of 401 patients found PuraStat hemostatic gel achieved 98.9% hemostasis for active gastrointestinal bleeding and was associated with low rebleeding rates when used prophylactically after operative endoscopy procedures.

KEY POINTS

- PuraStat achieved immediate hemostasis in 90 of 91 patients (98.9%) with active gastrointestinal bleeding across upper GI, biliopancreatic, and lower GI sites.
- Among 310 prophylactic applications after operative endoscopy, only 12 patients (3.9%) experienced bleeding events during follow-up, compared with 7.7% rebleeding after therapeutic use.
- The gel covered a median 97.9% of treated areas with application difficulty in only 1.7% of cases due to endoscope position, and no complications related to PuraStat use were reported.
- Applications included upper GI lesions (varices, ulcers, GAVE, post-resection), biliopancreatic procedures (post-sphincterotomy, post-papillectomy, WOPN drainage), and lower GI procedures (post-resection, post-dilation, radiation proctopathy).
- This registry represents the first evaluation of PuraStat in upper GI and biliopancreatic procedures, expanding evidence beyond previous lower GI indications.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e3a18a18-743c-11ee-b9a8-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.